Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Sandoz Group AG (QX) SDZNY

Alternate Symbol(s):  SDZXF

Healthcare Drug Manufacturers - Specialty & Generic
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (OTCQX:SDZNY)

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Business Wire September 24, 2025

Sandoz welcomes Quebec government support for Boucherville plant modernization project

Canada NewsWire August 27, 2025

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

GlobeNewswire August 12, 2025

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

GlobeNewswire August 7, 2025

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

GlobeNewswire July 30, 2025

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

GlobeNewswire July 1, 2025

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

GlobeNewswire June 2, 2025

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

GlobeNewswire May 21, 2025

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

GlobeNewswire April 30, 2025
View More News ››

Opinion & Analysis (OTCQX:SDZNY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (OTCQX:SDZNY)

Be the first to post on this bullboard.

Equity Metals Corp.

Equity Metals Corp.

Equity Metals Corporation engages in the acquisition, exploration, and development of mineral properties in Canada. It ...
View More »